Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
The Orphan Drug Act of 1983 was created to encourage pharmaceutical companies to develop drugs for so-called rare or ultra-rare diseases. The National Institutes of Health (NIH) defines rare diseas...
With patent loss looming, Takeda knocks proposed Velcade copycats in FDA petition Takeda’s multiple myeloma blockbuster Velcade is quickly running out of patent protection, but the drug maker has f...
Sanofi pays €120M to buy into AstraZeneca RSV program Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclon...
GW Pharmaceuticals, a UK based company, believes in growing its own cannabis plants, search for its ingredients and then come up with medicines that help the company in taking one more step towards...
Immune checkpoint activators are small molecules responsible for maintenance, modulation and regulation of immune responses. Its significance in Immuno therapeutics is backed by its functionality t...
Burn is a global public health problem, causing more than 180,000 deaths per year acros...
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
-Agonist.png "Toll-like Receptors Agonist")
